- Home
- ATHA vs NLSP Comparison
ATHA vs NLSP Comparison
Compare ATHA & NLSP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ATHA
- NLSP
- Stock Information
- Founded
- ATHA 2011
- NLSP 2015
- Country
- ATHA United States
- NLSP Switzerland
- Employees
- ATHA N/A
- NLSP N/A
- Industry
- ATHA Medicinal Chemicals and Botanical Products
- NLSP Biotechnology: Pharmaceutical Preparations
- Sector
- ATHA Health Care
- NLSP Health Care
- Exchange
- ATHA Nasdaq
- NLSP Nasdaq
- Market Cap
- ATHA 14.8M
- NLSP 12.4M
- IPO Year
- ATHA 2020
- NLSP 2021
- Fundamental
- Price
- ATHA $3.82
- NLSP $1.72
- Analyst Decision
- ATHA
- NLSP
- Analyst Count
- ATHA 0
- NLSP 0
- Target Price
- ATHA N/A
- NLSP N/A
- AVG Volume (30 Days)
- ATHA 48.3K
- NLSP 913.9K
- Earning Date
- ATHA 11-06-2025
- NLSP 10-06-2025
- Dividend Yield
- ATHA N/A
- NLSP N/A
- EPS Growth
- ATHA N/A
- NLSP N/A
- EPS
- ATHA N/A
- NLSP N/A
- Revenue
- ATHA N/A
- NLSP N/A
- Revenue This Year
- ATHA N/A
- NLSP N/A
- Revenue Next Year
- ATHA N/A
- NLSP N/A
- P/E Ratio
- ATHA N/A
- NLSP N/A
- Revenue Growth
- ATHA N/A
- NLSP N/A
- 52 Week Low
- ATHA $2.20
- NLSP $1.30
- 52 Week High
- ATHA $8.26
- NLSP $5.64
- Technical
- Relative Strength Index (RSI)
- ATHA 63.70
- NLSP 38.67
- Support Level
- ATHA $3.61
- NLSP $1.45
- Resistance Level
- ATHA $4.04
- NLSP $1.89
- Average True Range (ATR)
- ATHA 0.25
- NLSP 0.19
- MACD
- ATHA -0.16
- NLSP -0.03
- Stochastic Oscillator
- ATHA 20.92
- NLSP 26.24
About ATHA Athira Pharma Inc.
Athira Pharma Inc is a late clinical-stage biopharmaceutical company focused on developing small molecules engineered to restore neuronal health and slow neurodegeneration. Its pipeline candidates are; Fosgonimeton (ATH-1017) is a small molecule drug candidate designed to enhance the activity of the neurotrophic hepatocyte growth factor (HGF) system; ATH-1020 a novel, orally available, next-generation small molecule drug candidate designed to positively modulate the neurotrophic HGF system; ATH-1105 is a novel, orally available, next-generation, small molecule drug candidate designed to positively modulate the neurotrophic HGF system.
About NLSP NLS Pharmaceutics Ltd.
NLS Pharmaceutics Ltd a clinical-stage biopharmaceutical company focused on the discovery and development of inventive therapies for patients with rare and complex CNS disorders with unmet medical needs. Its compound, mazindol, a triple monoamine reuptake inhibitor and partial orexin receptor 2 agonist, in a proprietary ER formulation, is being developed for the treatment of narcolepsy, IH (follow-on indication), and potentially ADHD (back-up indication). Its lead products are Quilience, to treat narcolepsy and Nolazol, to treat ADHD.